{
  "source": "PA-Med-Nec-Wainua.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2326-2\nProgram Prior Authorization/Medical Necessity\nMedication Wainua™ (eplontersen)\nP&T Approval Date 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nWainua (eplontersen) is a transthyretin-directed antisense oligonucleotide indicated for the\ntreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in\nadults.\n2. Coverage Criteria a:\nA. Initial Authorization\n1. Wainua will be approved based on all of the following criteria:\na. Both of the following:\n(1) Diagnosis of hATTR amyloidosis with polyneuropathy\n-AND-\n(2) Documentation that the patient has a pathogenic TTR mutation (e.g., V30M)\n-AND-\nb. Prescribed by or in consultation with a neurologist\n-AND-\nc. Documentation of one of the following:\n(1) Patient has a baseline polyneuropathy disability (PND) score ≤ IIIb\n-OR-\n(2) Patient has a baseline FAP Stage 1 or 2\n-OR-\n(3) Patient has a baseline neuropathy impairment (NIS) score ≥ 10 and ≤ 130\n-AND-\nd. Patient has not had a liver transplant\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\ne. Presence of clinical signs and symptoms of the disease (e.g., peripheral\nsensorimotor polyneuropathy, autonomic neuropathy, motor disability, etc.)\n-AND-\nf. Patient is not receiving Wainua in combination with either of the following:\n(1) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran),\nTegsedi (inotersen)]\n-OR-\n(2) Transthyretin stabilizer [e.g., Vyndaqel/Vyndamax (tafamadis), Attruby\n(acoramidis)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Wainua will be approved based on both of the following criteria:\na. Documentation that the patient has experienced a positive clinical response to\nWainua therapy (e.g., improved neurologic impairment, motor function, quality of\nlife, slowing of disease progression, etc.)\n-AND-\nb. Patient is not receiving Wainua in combination with either of the following:\n(1) Oligonucleotide agents [e.g.",
    "mpairment, motor function, quality of\nlife, slowing of disease progression, etc.)\n-AND-\nb. Patient is not receiving Wainua in combination with either of the following:\n(1) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran),\nTegsedi (inotersen)]\n-OR-\n(2) Transthyretin stabilizer [e.g., Vyndaqel/Vyndamax (tafamadis), Attruby\n(acoramidis)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Wainua [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2024.\nProgram Prior Authorization/Medical Necessity - Wainua™ (eplontersen)\nChange Control\n2/2024 New program.\n2/2025 Added Attruby to Vyndaqel/Vyndamax and relabeled as transthyretin\nstabilizer agents not to be used in combination. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}